Efficacy and Safety of Oral Non-Statin Lipid-Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta-Analysis

Introduction

Dyslipidaemia remains a major contributor to atherosclerotic cardiovascular disease (ASCVD), and many patients fail to achieve recommended low-density lipoprotein cholesterol (LDL-C) targets despite statin therapy or are unable to tolerate statins. Oral non-statin therapies have emerged as important alternatives; however, their comparative efficacy and safety remain unclear.

Methods